News & Comment

Innovative Medicines Initiative projects focused on translational safety have developed a range of tools to improve preclinical assessments of potential drug toxicities, and demonstrated the value of integrating data from multiple companies.

Drug developers are re-advancing amylin analogues for obesity, two decades since the FDA approved the first of these hormone mimetics for diabetes.

Lorna Ewart, Chief Scientific Officer at Emulate, discusses the new opportunities and remaining challenges facing organs on chips.

Andy Plump, Takeda’s head of R&D, discusses the company’s evolving pipeline, therapeutic modalities, and upheaval in biotech, the NIH and the FDA.

Johnson & Johnson has discontinued development of aticaprant for depression with anhedonia, a blow to hopes for drugs for ‘domains’ of psychiatric disorders.